Changes from baseline to week 12 in secondary endpoints
| Parameter | Luseo 2.5 mg (n=80) | Luseo 5 mg (n=86) | Luseo 10 mg (n=79) | Placebo (n=83) |
| FPG (mmol/L) | −0.82 (95% CI −1.17 to −0.47) | −1.07 (95% CI −1.40 to −0.74) | −1.11 (95% CI −1.45 to −0.77) | −0.44 (95% CI −0.78 to −0.10) |
| PPG (mmol/L) | −2.14 (95% CI −2.80 to −1.48) | −1.65 (95% CI −2.26 to −1.04) | −2.39 (95% CI −3.04 to −1.75) | −0.92 (95% CI −1.56 to −0.28) |
| Body weight (kg) | −2.32 (95% CI −2.89 to −1.75) | −2.46 (95% CI −2.99 to −1.94) | −2.96 (95% CI −3.50 to −2.42) | −1.45 (95% CI −1.98 to −0.91) |
| Waist circumference (cm) | −2.08 (95% CI −3.08 to −1.08) | −2.46 (95% CI −3.38 to −1.54) | −2.77 (95% CI −3.74 to −1.796) | −1.74 (95% CI −2.69 to −0.794) |
FPG, fasting plasma glucose; luseo, luseogliflozin; PPG, postprandial plasma glucose.